The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Prodrugs—from Serendipity to Rational Design
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prodrugs: design and clinical applications
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,630
Self-citationThe mechanism of action of aspirin
Vane, J. R., & Botting, R. M. (2003) · Thrombosis Research · doi:10.1016/s0049-3848(03)00379-7 · Cited by 1,225
Mega, J. L., Simon, T., Collet, J.-P., Anderson, J. L., Antman, E. M., Bliden, K., Cannon, C. P., Danchin, N., Giusti, B., Gurbel, P., et al. (2010) · JAMA · doi:10.1001/jama.2010.1543 · Cited by 1,135
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Hörter, D., & Dressman, J. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00130-7 · Cited by 819
Codeine Intoxication Associated with Ultrarapid CYP2D6 Metabolism
Gasche, Y., Daali, Y., Fathi, M., Chiappe, A., Cottini, S., Dayer, P., & Desmeules, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041888 · Cited by 702
Smith, H. S. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60750-7 · Cited by 696
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689
Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics
van de Waterbeemd, H., Smith, D. A., Beaumont, K., & Walker, D. K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000407e · Cited by 599
Prodrug strategies to overcome poor water solubility
Stella, V. J., & Nti-Addae, K. W. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.013 · Cited by 554
Structure, function and regulation of carboxylesterases
Satoh, T., & Hosokawa, M. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.07.001 · Cited by 488
Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?
Dobson, P. D., & Kell, D. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2438 · Cited by 475 · cited 2×
“Paradoxically, amino acid esters and amides can also be used to enhance absorption and consequently oral drug delivery of parent drugs, because the brush-border membrane of intestinal epithelium possesses a considerable number of transporters for amino acids and peptides (Majumdar et al., 2004; Dobson and Kell, 2008).”
BackgroundParaoxonase-1 is a major determinant of clopidogrel efficacy
Bouman, H. J., Schömig, E., van Werkum, J. W., Velder, J., Hackeng, C. M., Hirschhäuser, C., Waldmann, C., Schmalz, H.-G., ten Berg, J. M., & Taubert, D. (2011) · Nature Medicine · doi:10.1038/nm.2281 · Cited by 465
Mechanisms of action of isoniazid
Timmins, G. S., & Deretic, V. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05467.x · Cited by 421
Netland, P. A., Landry, T., Sullivan, E. K., Andrew, R., Silver, L., Weiner, A., Mallick, S., Dickerson, J., Bergamini, M. V. W., Robertson, S. M., et al. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01177-1 · Cited by 417
Wallentin, L. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp296 · Cited by 409
SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., & Lee, W. W. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90267-1 · Cited by 402
Chemical Aspects of Selective Toxicity
ALBERT, A. (1958) · Nature · doi:10.1038/182421a0 · Cited by 401
Farid, N. A., Kurihara, A., & Wrighton, S. A. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009343005 · Cited by 397
Lessons Learned from Marketed and Investigational Prodrugs
Ettmayer, P., Amidon, G. L., Clement, B., & Testa, B. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0303812 · Cited by 384
Enzymes involved in the bioconversion of ester-based prodrugs
Liederer, B. M., & Borchardt, R. T. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20542 · Cited by 377
Structure, Function, and Regulation of Carboxylesterases
Hosokawa, M., & Satoh, T. (2006) · Toxicology of Organophosphate & Carbamate Compounds · doi:10.1016/b978-012088523-7/50017-x · Cited by 374
The Pharmacology of the Gastric Acid Pump: The H+,K+ ATPase
Sachs, G., Shin, J. M., Briving, C., Wallmark, B., & Hersey, S. (1995) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.001425 · Cited by 367
Beaumont, K., Webster, R., Gardner, I., & Dack, K. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489253 · Cited by 363
Human Carboxylesterase Isozymes: Catalytic Properties and Rational Drug Design
Imai, T. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.173 · Cited by 359
Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2
del Amo, E. M., Urtti, A., & Yliperttula, M. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.06.015 · Cited by 319
Current Progress on Esterases: From Molecular Structure to Function
Satoh, T., Taylor, P., Bosron, W. F., Sanghani, S. P., Hosokawa, M., & Du, B. N. L. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.488 · Cited by 295
Prodrug strategies in cancer therapy
Denny, W. A. (2001) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(01)01253-3 · Cited by 290
Chemistry of Covalent Inhibition of the Gastric (H+, K+)-ATPase by Proton Pump Inhibitors
Shin, J. M., Cho, Y. M., & Sachs, G. (2004) · Journal of the American Chemical Society · doi:10.1021/ja049607w · Cited by 283
Shi, D., Yang, J., Yang, D., LeCluyse, E. L., Black, C., Li, Y., Akhlaghi, F., & Yan, B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111807 · Cited by 279
Clinical Pharmacokinetics of Losartan
Sica, D. A., Gehr, T. W. B., & Ghosh, S. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544080-00003 · Cited by 258
Oseltamivir: A Review of its Use in Influenza
McClellan, K., & Perry, C. M. (2001) · Drugs · doi:10.2165/00003495-200161020-00011 · Cited by 257
Drug delivery to the retina: challenges and opportunities
Duvvuri, S., Majumdar, S., & Mitra, A. K. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.1.45 · Cited by 249
Writing Committee Members, Holmes, D. R., Dehmer, G. J., Kaul, S., Leifer, D., O'Gara, P. T., & Stein, C. M. (2010) · Circulation · doi:10.1161/cir.0b013e3181ee08ed · Cited by 223
The biochemistry and mechanism of action of acyclovir
Elion, G. B. (1983) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/12.suppl_b.9 · Cited by 217
Neuvonen, P. J., Backman, J. T., & Niemi, M. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847070-00003 · Cited by 216
Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin
Eisert, W. G., Hauel, N., Stangier, J., Wienen, W., Clemens, A., & van Ryn, J. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.203604 · Cited by 216
Balimane, P. V., Tamai, I., Guo, A., Nakanishi, T., Kitada, H., Leibach, F. H., Tsuji, A., & Sinko, P. J. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9298 · Cited by 214
Evidence from opiate binding studies that heroin acts through its metabolites
Inturrisi, C. E., Schultz, M., Shin, S., Umans, J. G., Angel, L., & Simon, E. J. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90616-1 · Cited by 212
Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology
Testa, B., & Mayer, J. M. (2003) · doi:10.1002/9783906390444 · Cited by 196
Guise, C. P., Abbattista, M. R., Singleton, R. S., Holford, S. D., Connolly, J., Dachs, G. U., Fox, S. B., Pollock, R., Harvey, J., Guilford, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3237 · Cited by 185
Hornykiewicz, O. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5741-y · Cited by 184
JORDAN, V (2007) · Steroids · doi:10.1016/j.steroids.2007.07.009 · Cited by 177
The Biochemistry of Drug Metabolism – An Introduction: Part 2. Redox Reactions and Their Enzymes
Testa, B., & Krämer, S. D. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790032 · Cited by 171
Delahoy, P. J., Magliano, D. J., Webb, K., Grobler, M., & Liew, D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.017 · Cited by 168
Erion, M. D., Reddy, K. R., Boyer, S. H., Matelich, M. C., Gomez-Galeno, J., Lemus, R. H., Ugarkar, B. G., Colby, T. J., Schanzer, J., & van Poelje, P. D. (2004) · Journal of the American Chemical Society · doi:10.1021/ja031818y · Cited by 165
Apnea in a child after oral codeine: a genetic variant ? an ultra-rapid metabolizer
Voronov, P., Przybylo, H. J., & Jagannathan, N. (2007) · Pediatric Anesthesia · doi:10.1111/j.1460-9592.2006.02182.x · Cited by 156
Prodrugs : challenges and rewards
Stella, V. J. (2007) · Cited by 153
Physicochemical and drug-delivery considerations for oral drug bioavailability
Chan, O. H., & Stewart, B. H. (1996) · Drug Discovery Today · doi:10.1016/1359-6446(96)10039-8 · Cited by 149
Prodrug Approaches for Enhancing the Bioavailability of Drugs with Low Solubility
Müller, C. E. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900114 · Cited by 146
Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
Sideras, K., Ingle, J. N., Ames, M. M., Loprinzi, C. L., Mrazek, D. P., Black, J. L., Weinshilboum, R. M., Hawse, J. R., Spelsberg, T. C., & Goetz, M. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8931 · Cited by 145
Testa, B., & Krämer, S. D. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790169 · Cited by 139
Pharmacology and pharmacokinetics of fosphenytoin
Browne, T. R., Kugler, A. R., & Eldon, M. A. (1996) · Neurology · doi:10.1212/wnl.46.6_suppl_1.3s · Cited by 136
The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinsons Disease
Khor, S. P., & Hsu, A. (2007) · Current Clinical Pharmacology · doi:10.2174/157488407781668802 · Cited by 135
Neuvonen, P. J. (2010) · PubMed · Cited by 133
Stella, V. J., Tilley, J., Oliyai, R., Maag, H., Hageman, M. J., & Borchardt, R. T. (2007) · Springer eBooks · doi:10.1007/978-0-387-49785-3 · Cited by 131
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
Gruer, P. J. K., Vega, J. M., Mercuri, M. F., Dobrinska, M. R., & Tobert, J. A. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00442-7 · Cited by 130
Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence β-lactams)
Bentley, R. (2009) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-009-0553-8 · Cited by 129
Wire, M. B., Shelton, M. J., & Studenberg, S. D. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645020-00002 · Cited by 127
Prodrugs: Some Thoughts and Current Issues
Stella, V. J. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22205 · Cited by 126
Prodrug research: futile or fertile?
Testa, B. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.005 · Cited by 124
Role of Metabolism in Ocular Drug Delivery
Duvvuri, S., Majumdar, S., & Mitra, A. K. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335342 · Cited by 122
Liver-Targeted Drug Delivery Using HepDirect Prodrugs
Erion, M. D., van Poelje, P. D., MacKenna, D. A., Colby, T. J., Montag, A. C., Fujitaki, J. M., Linemeyer, D. L., & Bullough, D. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075903 · Cited by 119
Majumdar, S., Duvvuri, S., & Mitra, A. K. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.006 · Cited by 114
Hydrolysis in drug and prodrug metabolism : chemistry, biochemistry, and enzymology
Testa, B., & Mayer, J. M. (2003) · Medical Entomology and Zoology · Cited by 113
Anderson, R. F., Shinde, S. S., Hay, M. P., Gamage, S. A., & Denny, W. A. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0209363 · Cited by 111
Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
KAUKONEN, K. ‐., Olkkola, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050405 · Cited by 111
Clopidogrel Pharmacogenomics and Risk of Inadequate Platelet Inhibition: US FDA Recommendations
Ellis, K., Stouffer, G. A., McLeod, H. L., & Lee, C. R. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.143 · Cited by 108
Hypoxia-Activated Prodrugs in Cancer Therapy: Progress to the Clinic
Denny, W. A. (2010) · Future Oncology · doi:10.2217/fon.10.1 · Cited by 100
Furfine, E. S., Baker, C. T., Hale, M. R., Reynolds, D. J., Salisbury, J. A., Searle, A. D., Studenberg, S. D., Todd, D., Tung, R. D., & Spaltenstein, A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.791-798.2004 · Cited by 98
Guise, C. P., Wang, A. T., Theil, A., Bridewell, D. J. A., Wilson, W. R., & Patterson, A. V. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.014 · Cited by 87
DRUG FOCUS: Pharmacogenetic Studies Related to Cyclophosphamide-Based Therapy
Pinto, N. R., Ludeman, S. M., & Dolan, M. E. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.134 · Cited by 87
Cowen, R. L., Williams, K. J., Chinje, E. C., Jaffar, M., Sheppard, F. C. D., Telfer, B. A., Wind, N. S., & Stratford, I. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2698 · Cited by 86
Patterson, A. V., Barham, H. G., Chinje, E. C., Adams, G., Harris, A. L., & Stratford, I. J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.478 · Cited by 85
Sinko, P. J., & Balimane, P. V. (1998) · Biopharmaceutics & Drug Disposition · Cited by 84
Designing for topical delivery: Prodrugs can make the difference
Sloan, K. B., & Wasdo, S. C. (2003) · Medicinal Research Reviews · doi:10.1002/med.10048 · Cited by 79
The design and bioactivation of presystemically stable prodrugs
Svensson, L.-Å., & Tunek, A. (1988) · Drug Metabolism Reviews · doi:10.3109/03602538809049622 · Cited by 73
Amino Acid Transporter ATB0,+ as a Delivery System for Drugs and Prodrugs
Ganapathy, M. E., & Ganapathy, V. (2005) · Current Drug Targets - Immune Endocrine & Metabolic Disorders · doi:10.2174/156800805774912953 · Cited by 73
Brauch, H. B., & Jordan, V. C. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.032 · Cited by 71
Personalized Therapy in Pain Management: Where Do We Stand?
Stamer, U. M., Zhang, L., & Stüber, F. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.47 · Cited by 70
Hicks, K. O., Myint, H., Patterson, A. V., Pruijn, F. B., Siim, B. G., Patel, K., & Wilson, W. R. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.05.049 · Cited by 69
Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies
Papot, S., Tranoy‐Opalinski, I., Tillequin, F., Florent, J., & GESSON, J. ‐. (2002) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023354173 · Cited by 66
Improved passive oral drug delivery via prodrugs
Taylor, M. D. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00104-f · Cited by 62
Tsuda, M., Terada, T., Irie, M., Katsura, T., Niida, A., Tomita, K., Fujii, N., & Inui, K. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.102830 · Cited by 61
Krämer, S. D., & Testa, B. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890214 · Cited by 59
Leenders, R. G. G., Damen, E. W. P., Bijsterveld, E. J. A., Scheeren, H. W., Houba, P. H. J., van der Meulen‐Muileman, I. H., Boven, E., & Haisma, H. J. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00095-4 · Cited by 57
Hellberg, M. R., Ke, T.-L., Haggard, K. S., Klimko, P. G., Dean, T. R., & Graff, G. (2003) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/108076803321637627 · Cited by 50
Tirkkonen, T., & LAINE, K. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.017 · Cited by 50
Midodrine: a selective α-adrenergic agonist for orthostatic hypotension and dialysis hypotension
Cruz, D. N. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.4.835 · Cited by 44
Boyer, S. H., Sun, Z., Jiang, H., Esterbrook, J., Gomez‐Galeno, J., Craigo, W. A., Reddy, K. R., Ugarkar, B. G., MacKenna, D. A., & Erion, M. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0607449 · Cited by 43
Prodrug Strategy for Enhancing Drug Delivery via Skin
Fang, J., & Leu, Y. (2006) · Current Drug Discovery Technologies · doi:10.2174/157016306780136772 · Cited by 41
Prami, T., Ryynänen, A., Vahlberg, T. J., Irjala, K., Klaukka, T., Huupponen, R., & Laine, K. (2008) · Drug Safety · doi:10.2165/00002018-200831030-00004 · Cited by 26
Solubility Issues in Early Discovery and HTS
Di, L., & Kerns, E. H. (2007) · Springer eBooks · doi:10.1007/978-0-387-69154-1_4 · Cited by 22
Prodrug Strategies in Drug Design
Rautio, J. (2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527633166.ch1 · Cited by 10
Self-citationMacKenna, D. A., Montag, A. C., Boyer, S. H., Linemeyer, D. L., & Erion, M. D. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0953-5 · Cited by 6
The Impact of Pharmacogenetics on the Clinical Outcomes of Prodrugs
Bai, J. P. F., Pacanowski, M., Rahman, A., & Lesko, L. L. (2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527633166.ch16 · Cited by 2
Cited by
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
The expanding role of prodrugs in contemporary drug design and development
Rautio, J., Meanwell, N. A., Di, L., & Hageman, M. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.46 · Cited by 767
Self-citationReactive‐Oxygen‐Species‐Responsive Drug Delivery Systems: Promises and Challenges
Saravanakumar, G., Kim, J., & Kim, W. J. (2017) · Advanced Science · doi:10.1002/advs.201600124 · Cited by 675
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Metadata
- Authors
- Huttunen, K. M., Raunio, H., & Rautio, J.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 63
- Issue
- 3
- Pages
- 750-771
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2166967403
- Cited by
- 505
- References
- 96
- FWCI
- 15.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.